Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353114 | 0.83 | ALPI (0.43) | GABBR2GABBR1CA2CA9CA1 | |
| SCHEMBL29498021 | 0.70 | LOXL2 (0.52) | LOXL2TRPA1GABBR2GABBR1TAAR1 | |
| SCHEMBL29498042 | 0.70 | LOXL2 (0.52) | LOXL2TRPA1GABBR2GABBR1TAAR1 | |
| SCHEMBL16434845 | 0.69 | LOXL2 (0.50) | LOXL2TRPA1TAAR1IDO1AGXT | |
| SCHEMBL6034394 | 0.68 | GABBR2 (0.42) | GABBR2GABBR1IDO1 | |
| SCHEMBL355063 | 0.68 | CYP2C19 (0.47) | GABBR2GABBR1CA2TAAR1CA9 | |
| SCHEMBL11280400 | 0.68 | TRPA1 (0.61) | LOXL2TRPA1TAAR1IDO1AGXT | |
| SCHEMBL776965 | 0.68 | LOXL2 (0.48) | LOXL2CA2TAAR1CA1IDO1 | |
| Hydrochloric Acid SCHEMBL14764546 | 0.67 | LOXL2 (0.48) | LOXL2TRPA1TAAR1IDO1AGXT | |
| SCHEMBL31344410 | 0.67 | CYP1A2 (0.52) | CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101124200-A | Methods and fluorinated compositions for treating amyloid-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-02-13 | — | — | CN | disclosed |
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | LOXL2 2084/4885TRPA1 3386/4885GABBR2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.